Related Experiment Video
Updated: May 17, 2025
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
360
Predictive Value of IL-6 and PDGF-AA for 28-Day Mortality Risk in Critical Ill Patients
1Department of Infectious Diseases and Clinical Microbiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100043, People's Republic of China.
International Journal of General Medicine
|May 15, 2025
Summary
Higher levels of interleukin-6 (IL-6) and platelet-derived growth factor AA (PDGF-AA) predict 28-day mortality in critically ill patients. Combining these biomarkers with SOFA scores improves mortality prediction accuracy.
Area of Science:
- Critical Care Medicine
- Biomarker Discovery
- Precision Medicine
Background:
- Prognostic biomarkers are crucial for improving outcomes in critically ill patients.
- Precision medicine requires accurate identification of factors predicting mortality.
- Existing prognostic tools may benefit from novel biomarker integration.
Purpose of the Study:
- To evaluate the prognostic value of interleukin-6 (IL-6) and platelet-derived growth factor AA (PDGF-AA).
- To assess the predictive capability of IL-6 and PDGF-AA for 28-day mortality in critically ill individuals.
- To explore the combined predictive power of these biomarkers with established scoring systems.
Main Methods:
- Recruited 199 critically ill patients from an emergency department.
- Measured IL-6 and PDGF-AA levels using Luminex assay.
- Calculated SOFA and APACHE II scores and performed correlation, logistic regression, and ROC analyses.
Main Results:
- Elevated IL-6 and PDGF-AA levels were observed in non-survivors (P<0.05).
- IL-6 and PDGF-AA independently predicted 28-day mortality (OR=1.003, 1.002).
- Combined IL-6 and SOFA achieved an AUROC of 0.892; IL-6, PDGF-AA, and SOFA achieved 0.905.
Conclusions:
- Serum IL-6 and PDGF-AA levels are important prognostic indicators in critical illness.
- Combining IL-6 and PDGF-AA with SOFA scores enhances prediction of 28-day mortality.
- Monitoring these biomarkers can aid in risk stratification and personalized treatment strategies.
